Medicine
Encelto 440000 units implant
Encelto 440000 units implant is a prescription medicine containing Revakinagene taroretcel for intravitreal use, marketed by Neurotech Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not freeze or refrigerate. 4. Store ENCELTO in the corepack at 16º to 37ºC…
Key facts
- Active ingredient (INN)
- Revakinagene taroretcel
- Brand
- Encelto
- Strength
- 440000 units
- Dosage form
- Implant
- Route
- Intravitreal
- Packs
- 1 capsule
- Marketing authorisation holder
- Neurotech Pharmaceuticals
- Manufacturer
- Neurotech Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Do not freeze or refrigerate. 4. Store ENCELTO in the corepack at 16º to 37ºC (61º to 99ºF) until ready for use. 3.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 12 March 2025
- Identifiers
- RxCUI 2708837, 2708843DailyMed set ID 1ae9482a-b478-4e21-9166-b5fd52d3ef9cNDC 82958-501Application BLA125798
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 capsule in 1 container / 1 implant in 1 capsule | 82958-501-01 | Neurotech Pharmaceuticals | 12 March 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Revakinagene taroretcel is a prescription medicine indicated for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel). It is available as implants for intravitreal use. MedsAcross supplies Revakinagene taroretcel for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Revakinagene taroretcelFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ENCELTO prescribing information (Neurotech Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Encelto 440000 units implant for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.